Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering ...

The cancer diagnostics and treatment company priced shares above their earlier target range and might signal a renewed ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of ...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...